Skip to Main Content

A combination treatment that pairs Amgen’s KRAS-blocking drug Lumakras with another of its targeted cancer medicines showed improved tumor response rates in patients with advanced colon cancer, the company said Thursday.

Amgen secured U.S. approval of Lumakras in May to treat patients with lung cancer caused by a genetic mutation to the KRAS protein. But the pill’s benefit in other types of solid tumors where KRAS also plays a role has proven to be more modest, necessitating a search for combination treatments that might boost efficacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment